HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

9- chloro- 2- (2- furyl)- 5- phenylacetylamino(1,2,4)triazolo(1,5- c)quinazoline

structure in first source

Also Known As:

MRS 1220; MRS-1220

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline: 3

Experts

1.	Broadley, Kenneth J: 1 article (03/2004)
2.	Gardner, Neil M: 1 article (03/2004)
3.	Yates, Lisa: 1 article (03/2004)
4.	Auchampach, John: 1 article (10/2002)
5.	Black, Richard G: 1 article (10/2002)
6.	Cross, Heather R: 1 article (10/2002)
7.	Murphy, Elizabeth: 1 article (10/2002)
8.	Steenbergen, Charles: 1 article (10/2002)
9.	Levitsky, S: 1 article (02/2001)
10.	McCully, J D: 1 article (02/2001)

Related Diseases

1.	Apnea 03/01/2004 - "Improved rate and extent of recovery of papillary muscles by APNEA (15 minutes, 94.8 +/- 3.1%) was prevented by the A3 receptor antagonist, MRS-1220 (10 M). "
2.	Ischemia 10/01/2002 - "To determine the role of depressed heart rate and to confirm A(3)AR-specific signaling, hearts were paced at 480 beats/min with or without 60 nmol/l MRS-1220 (A(3)AR-specific inhibitor) and then subjected to ischemia-reperfusion. " 02/01/2001 - "GR-69019X (A(1)/A(3)) and MRS-1191/MRS-1220 (A(3)) significantly increased infarct size in APC hearts when administered before ischemia and significantly decreased functional recovery when administered during both ischemia and reperfusion (P < 0.05 vs. APC). "
3.	Infarction (Infarctions) 02/01/2001 - "GR-69019X (A(1)/A(3)) and MRS-1191/MRS-1220 (A(3)) significantly increased infarct size in APC hearts when administered before ischemia and significantly decreased functional recovery when administered during both ischemia and reperfusion (P < 0.05 vs. APC). "

Related Drugs and Biologics

1.	MRS 1191